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Abstract
AIM
To assess in rodent and human adipocytes the antili-
polytic capacity of hexaquis(benzylammonium) deca-
vanadate (B6V10), previously shown to exert antidia-
betic effects in rodent models, such as lowering free 
fatty acids (FFA) and glucose circulating levels.
METHODS
Adipose tissue (AT) samples were obtained after 
informed consent from overweight women undergoing 
plastic surgery. Comparison of the effects of B6V10 
and reference antilipolytic agents (insulin, benzylamine, 
vanadate) on the lipolytic activity was performed on 
adipocytes freshly isolated from rat, mouse and human 
AT. Glycerol release was measured using colorimetric 
assay as an index of lipolytic activity. The influence of 
B6V10 and reference agents on glucose transport into 
human fat cells was determined using the radiolabelled 
2-deoxyglucose uptake assay.
RESULTS
In all the species studied, B6V10 exhibited a dose-
dependent inhibition of adipocyte lipolysis when 
triglyceride breakdown was moderately enhanced 
by β-adrenergic receptor stimulation. B6V10 exerted 
on human adipocyte a maximal lipolysis inhibition of 
glycerol release that was stronger than that elicited 
by insulin. However, B6V10 did not inhibit basal and 
maximally stimulated lipolysis. When incubated at dose 
≥ 10 µmol/L, B6V10 stimulated by twofold the glucose 
uptake in human fat cells, but - similarly to benzylamine 
- without reaching the maximal effect of insulin, while 
it reproduced one-half of the insulin-stimulation of 
lipogenesis in mouse fat cells. 
CONCLUSION
B6V10 exerts insulin-like actions in adipocytes, including 
lipolysis inhibition and glucose transport activation. 
B6V10 may be useful in limiting lipotoxicity related to 
obesity and insulin resistance. 
Key words: Adipocyte; Lipolysis; Amine oxidases; Insulin 
resistance; Obesity; Hydrogen peroxide; Vanadium; 
Antidiabetics
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This study investigates in murine and human 
adipocytes the antilipolytic properties of a conjugate 
of benzylamine and decavanadate (B6V10), already 
reported to lower hyperglycaemia in diabetic rodents. 
Data indicated that the conjugate dose-dependently 
inhibited submaximal activation of lipolysis in all the 
species studied. Such antilipolytic action deals with the in 
vivo FFA-lowering properties already described for B6V10 
in diabetic rats. B6V10 also activated lipogenesis and 
glucose transport in fat cells. B6V10 should therefore 
be useful in preventing the lipotoxicity constituted by 
the unrestrained lipolytic activity of insulin-resistant 
adipocytes in obese individuals presenting type 2 
diabetes, a state named diabesity. 
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INTRODUCTION
In obesity, the excessive enlargement of the adipose 
tissue (AT) is often associated with type 2 diabetes 
and morbid complications, especially when the hyper­
trophied fat depots are located in the intra­abdominal 
cavity (known as visceral fat). More than a decade 
ago, the links between fatness and altered glucose 
and lipid handling led to propose the term diabesity 
to define a complex disease distinct from “healthy” 
obesity[1]. The function of AT is not restricted to lipid 
storage: Indeed, it is also an endocrine organ, secreting 
numerous adipokines. Therefore, the excess of AT can 
be associated with insulin resistance[2,3], endocrine, 
metabolic and inflammatory disturbances, increasing 
the risk of co­morbidities, such as hypertension and 
dyslipidaemia. However, all these disorders, known 
as metabolic syndrome[4], not only co­exist with 
hypertrophied lipid storage but also with excessive 
lipid mobilization since the entire lipid turnover is 
dysregulated in diabesity. In fact, the circulating levels 
of the products of adipocyte lipolysis, namely free fatty 
acids (FFA) and glycerol, are dramatically elevated in 
obese individuals[5]. Such increase is likely resulting 
from a defective responsiveness of the adipocytes 
to the antilipolytic action of insulin. It is important to 
mention that insulin not only stimulates triglyceride 
synthesis, but also inhibits triglyceride breakdown, 
lowering basal lipolysis in fat cells and reducing FFA 
and glycerol blood levels. Therefore, in obese subjects 
with insulin resistance, the hypertrophied adipocytes 
release excessive amounts of FFA, which are not a 
good fuel supply to the other organs, and even hamper 
carbohydrate utilization. This contributes to maintaining 
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insulin resistance and its deleterious outcomes. 
Especially when occurring in visceral AT, such excessive 
lipolysis results in a high flux of FFA toward the liver, 
causing hepatosteatosis, inflammation, and worsening 
dyslipidemia. It is admitted that subjects with visceral 
fat have higher postprandial FFA and are at a higher risk 
of fatty liver disease and hepatic insulin resistance[6­8]. 
Indeed, clinical studies have demonstrated that the 
insulin resistance occurring in excessive AT affects 
metabolic parameters and increases liver damage[9]. 
Excessive FFA also have toxic effects in other organs 
(e.g., alteration of insulin secretion in pancreas[10]), that 
contribute to exacerbate hyperinsulinemia and insulin 
resistance. At the cellular level, excessive FFA supply 
impairs mitochondrial function and leads to abnormal 
lipid oxidation, further disturbing lipid turnover and 
cell survival. All these effects of excessive FFA belong 
to a network of mechanisms currently defined as 
lipotoxicity[11].
Since unrestrained AT lipolysis results in increased 
fatty acid release, leading to lipotoxicity, the search for 
antilipolytic drugs has been re­considered recently as a 
promising approach to delay and/or reverse the onset 
of insulin resistance in diabesity. Consequently, many 
pharmacological agents are under investigation with the 
objective of reproducing and surpassing the beneficial 
effects of the classical antilipolytic agent Acipimox, 
reported to transiently alleviate insulin resistance 
in obese subjects[12]. Agonists of Gi­protein coupled 
receptors endowed with such antilipolytic properties 
have been reviewed elsewhere[5]. In this context, we 
aimed to verify in adipocytes the antilipolytic properties 
of a potential antidiabetic agent previously characterized 
as an insulin­mimicker on its basis to activate glucose 
transport in adipocytes from rodent models[13].
Our interest was therefore focused in searching 
how an arylalkylamine vanadium salt, endowed with 
insulin­like actions regarding glucose disposal[14], was 
able to directly reduce the lipolytic activity of freshly 
isolated adipocytes. Our previous studies showed that 
hexaquis(benzylammonium) decavanadate, the formula 
of which is (C7H10N)6V10O28.2H2O, is a salt conjugate 
of benzylamine and decavanate (B6V10) acting as a 
substrate for semicarbazide sensitive amine oxidase/
vascular adhesion protein­1 (SSAO/VAP­1)[15]. This 
enzyme is abundant at the surface of adipocytes and 
generates hydrogen peroxide when oxidizing its amine 
substrates. In the presence of B6V10, SSAO/VAP­1 
also generated substantial amount of peroxovanadium, 
which, via phosphatase inhibition, was able to trigger 
insulin signalling downstream of the insulin receptor and 
to activate glucose transport in rodent adipocytes in the 
complete absence of insulin[16]. Chronic administration of 
B6V10 to rat or mouse models of diabetes substantially 
lowered blood glucose levels[13]. In addition, B6V10 
normalized the plasma concentration of non-esterified 
fatty acids in severely diabetic rats[13]. Our present study 
consisted in a comparative approach testing under 
various conditions the putative antilipolytic actions of 
B6V10 in murine and human adipocytes. 
We first tested increasing doses of B6V10 (0.1 to 
100 µmol/L) on the triglyceride breakdown (lipolysis 
releasing FFA and glycerol) in rat adipocytes. Then a 
broader range of B6V10 doses (1 nmol/L to 100 µmol/L) 
was tested on the lipolytic and lipogenic responses of 
mouse adipocytes. Finally, our observations showed 
for the first time in human adipocytes a substantial 
antilipolytic action of supramicromolar doses of B6V10, 
which also activated glucose uptake. 
MATERIALS AND METHODS
Patients and human adipocyte preparations
Adipocytes were isolated from samples of subcutaneous 
adipose tissue obtained from women undergoing 
abdominal lipectomy under the control of plastic sur­
gery staff of Rangueil Hospital (Toulouse, France). A 
total of 13 overweight women (age range: 30­48 year, 
BMI = 25.9 ± 1.1 kg/m2) were incorporated in the 
study following agreement of the INSERM guidelines 
and local ethic committee. The surgically removed 
pieces of human adipose tissue were placed in sterile 
plastic box, and transferred in less than one hour to the 
laboratory. The samples were immediately subjected to 
collagenase digestion at 37 ℃ to obtain freshly isolated 
adipose cells. To do so, pieces of adipose tissue were 
minced with scissors in Krebs­Ringer salt solution pH 
7.5 containing 15 mmol/L sodium bicarbonate, 10 
mmol/L HEPES and 3.5% of fat­depleted bovine serum 
albumin (KRBHA), and 5.5 mmol/L glucose. For the cell 
preparations used for glucose uptake assays, glucose 
was replaced by 2 mmol/L pyruvate. After digestion 
with 1 mg/mL collagenase type II for approximately 45 
min under agitation, buoyant adipocytes were separated 
by filtration through a 300 µmol/L mesh­screen and 
carefully washed in fresh medium to obtain adipocyte 
suspensions as previously described[17]. Final adipocyte 
suspensions averaged 14.5 ± 1.4 mg cell lipids/400 µL 
unless otherwise stated. 
Rodent adipocyte preparations
The same procedure as above was applied for rat and 
mouse adipocyte preparations. A total of 10 male 
Wistar rats were purchased at Charles River (L’Arbresle, 
France) and were sacrificed according to INSERM 
guidelines for adipocyte preparation as previously re­
ported[18]. Rat adipocytes were used at 15.3 ± 1.0 mg 
lipids/400 µL for the preliminary tests. Adipocytes were 
isolated from intra­abdominal adipose tissues obtained 
from male and female C57BL/6 mice. A total of 12 mice 
were used as already described[19] for the preparation of 
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and incubation were performed in disposable plastic 
wares at 37 ℃, as described[17]. All the tested agents 
were added to 400 µL of fat cell suspension in KRBHA 
under the form of 4 µL of a dilution extemporaneously 
done to reach the final indicated concentration. The 
agents were incubated with the fat cells at 37 ℃ under 
constant, gentle, shaking during 90 min. Incubations 
were stopped by placing the incubation tubes on ice. As 
already documented, lipolytic activity was determined 
by using glycerol release as an index[20], since FFA 
release follows parallel variations in our experimental 
conditions[21]. Once the buoyant adipocytes were 
frosted, 150 µL of medium were removed for glycerol 
spectrophotometric measurement at 340 nm, after 
addition of 1.5 mL of chromogenic mixture (0.6 mmol/
L NAD, 1.4 mmol/L ATP, 0.2 mol/L glycine, 1 mol/L 
hydrazine, with 15 unit/mL glycerol phosphate dehydro­
genase, and 0.6 unit/mL glycerokinase, pH 9.8), as 
previously described[22].
Glucose transport assay and de novo lipogenic activity 
An isotopic dilution of [3H]­2­deoxyglucose (2­DG) 
was added at a final concentration of 0.1 mmol/L 
(approximately 1300000 dpm/vial) to 400 µL of cell 
suspension after 45 min preincubation with the tested 
agents. Human fat cells were incubated for additional 
10 min and then stopped with 100 µL of 100 µmol/L 
cytochalasin B. Aliquotes (200 µL) of shaken cell 
suspension were immediately centrifuged in microtubes 
containing dinonyl phthalate of density 0.98 g/mL, 
which allowed to separate the adipocytes as previously 
described[23]. The radiolabelled hexose internalized 
in viable fat cells (upper part of the tubes) was then 
counted in scintillation vials. The extracellular 2­DG 
present was determined using adipocytes whose 
transport activity was previously blocked by cytochalasin 
B at time 0. It did not exceed 1% of the maximum 2­DG 
uptake in the presence of insulin and was subtracted 
from the assays.
De novo lipogenic activity was determined by 
quantifying the D­[3­3H]­glucose incorporation into 
lipids in mouse fat cells, according to[21]. They were 
incubated at 37 ℃ for 120 min in the same incubation 
medium as above, only containing only 0.6 mmol/L of 
isotopic glucose dilution as source of carbohydrates. The 
same vials were used for incubation, lipid extraction in 
an organic mixture for liquid scintillation (InstaFluorPlus) 
and counting of the labelled neo­synthesized lipids, 
following a procedure adapted from Moody et al[24].
Chemicals
Hexaquis(benzylammonium) decavanadate (B6V10) 
was synthesized and purified by Fernando Albericio 
and coworkers as previously detailed[16] and kindly 
given by Genmedica (Barcelona, Spain). Benzylamine, 
sodium orthovanadate, (­)­isoprenaline hydrochloride 
(isoproterenol), atrial natriuretic peptide (ANP), coll­
agenase type II and other reagents were from Sigma­
Aldrich (Saint Quentin Fallavier, France). 2­DG and D­3­
[3H]­glucose were from Perkin Elmer (Boston, MA, 
United States). 
Statistical analysis
Results are presented as means ± standard error of the 
means (SEM) of (n) observations. Statistical analysis 
for comparisons between B6V10 and respective control 
used Student’s t test.
RESULTS
Effects of B6V10 in rat adipocytes
It is necessary to moderately activate lipolysis to 
detect whether a putative antilipolytic agent is able 
to limit triglyceride breakdown. This approach was 
first performed in rat adipocytes. The β­adrenergic 
agonist isoprenaline increased lipolytic activity in a 
typical concentration­dependent manner, and reached 
maximal activation at 1­10 µmmol/L. Addition of 100 
µmmol/L of hexaquis(benzylammonium) decavanadate 
(B6V10) to increasing doses of isoprenaline impaired 
the β­adrenergic stimulation, clearly shifting the 
dose­response curve (Figure 1A). Noteworthy, the 
conjugate B6V10 did not alter the maximal effect of the 
highest isoprenaline dose. Similarly, the lowest dose 
of isoprenaline did not activate lipolysis sufficiently to 
allow any detection of B6V10 effect. Then, increasing 
concentrations of B6V10 were tested against an 
intermediate dose of isoprenaline (10 nmmol/L). In 
this condition, B6V10 dose­dependently inhibited the 
lipolytic activation induced by the β­agonist (Figure 1B). 
The conjugate therefore exhibited a clear and rapid 
antilipolytic effect in rat adipocytes, a cell model in which 
B6V10 has been already reported to mimic another 
insulin action: Glucose transport activation[13]. 
Effects of B6V10 in mouse adipocytes 
Further studies performed on mouse adipocytes 
confirmed that increasing doses of B6V10 did not 
affect basal lipolysis, which was readily activated by 
isoprenaline (Figure 2A). Such lack of effect indicated 
that the conjugate was not lipolytic. However, other 
recognized antilipolytic agents, including insulin, were 
also unable to lower basal glycerol release (not shown). 
Consistent with our data obtained using rat adipocytes, 
activation of lipolytic activity was required to unmask 
putative antilipolytic effects. Consequently, B6V10 was 
tested at 1 µmmol/L in the presence of increasing doses 
of isoprenaline (Figure 2B). B6V10 did not impair the 
maximal lipolysis promoted by 0.1 and 1 µmmol/L of the 
β­adrenergic agonist, but it impaired the submaximal 
stimulation by 1 nmol/L and 10 nmol/L isoprenaline. 
When tested separately, the components of B6V10, 
benzylamine and sodium orthovanadate, did not alter 
the lipolytic effect of 10 nmol/L isoprenaline, while their 
combination at 100 µmol/L each was as antilipolytic as 
B6V10 (Figure 2B).
Carpéné C et al . Antilipolytic effect of B6V10
147 April 15, 2017|Volume 8|Issue 4|WJD|www.wjgnet.com
Thus, the antilipolytic action of B6V10 was detectable 
only when lipolysis was mildly activated by the β­ad­
renergic agonist isoprenaline. This could suggest 
that B6V10 was acting by antagonizing activation of 
β­adrenergic receptors. To ascertain that an antagonism 
at β­adrenergic receptors was not mandatory to 
observe a response to the conjugate, we verified its 
direct effect on glucose utilization in mouse fat cells. 
When tested alone at 10 µmol/L, B6V10 reproduced 
49.0% ± 7.8% of the de novo lipogenic action of 100 
nmol/L insulin, which was equivalent to a threefold 
increase over the basal values of the incorporation of 
radiolabelled glucose into the lipids of mouse adipocytes 
(n = 5, not shown). At 100 µmol/L, B6V10 reached 
85.0% ± 3.5% of the maximal lipogenic effect of 
insulin. These data supported that the conjugate was 
active per se on adipocytes through a mechanism 
distinct from antagonism at β­adrenoceptors, since 
these G­coupled receptors were not activated during 
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Figure 1  Influence of B6V10 on isoprenaline-induced lipolysis in rat adipocytes. Glycerol release was determined in rat fat cells incubated 90 min without 
(basal) and with increasing concentrations of isoprenaline alone (control, black symbols) or with the indicated doses of B6V10. Basal lipolysis (0.39 ± 0.06 µmol 
glycerol/100 mg lipid/90 min) was set at 0% while maximal lipolytic effect of 10 µmol/L isoprenaline (1.73 ± 0.14 µmol glycerol/100 mg lipid/90 min) was set at 100%. A: 
Antilipolytic effect of 100 µmol/L B6V10 (red diamonds) on dose-dependent activation by isoprenaline; B: Dose-dependent inhibition by B6V10 of the lipolysis 
induced by 10 nmol/L isoprenaline (iso alone). Mean ± SEM of 8-10 determinations. Significantly different from corresponding condition without B6V10 at: aP < 0.05, 







Figure 2  Influence of B6V10 on basal and isoprenaline-stimulated lipolysis in mouse adipocytes. Glycerol release was determined after 90-min incubation 
of mouse fat cells without (basal, closed square) or with the indicated concentrations of isoprenaline (open diamonds) or B6V10 (red symbols). A: Lack of lipolytic 
effect of increasing doses of B6V10 (red circles); B: Comparison of the inhibition of isoprenaline-stimulated lipolysis by 1 µmol/L B6V10 (red diamonds), 0.1 mmol/L 
benzylamine (open circle), 0.1 mmol/L vanadate (closed circle), or their combination (closed triangle). Mean ± SEM of 8 determinations. Significantly different from 
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confirmed our previous characterization of B6V10 as 
an insulin­mimicking agent, acting through a hydrogen 
peroxide­dependent mechanism on the stimulation of 
glucose transport into fat cells[13]. In this context, the 
antilipolytic effect and the lipogenic effects of B6V10 
could be considered as additional facets to the multiple 
B6V10 insulin­mimicking properties. 
Translational studies on B6V10 antilipolytic action 
Antilipolytic effects of insulin and B6V10 were then 
compared in mouse fat cells and in human adipocytes. 
In mouse, lipolysis was moderately activated by 10 
nmol/L isoprenaline, reaching 1.28 ± 0.11 µmoles 
glycerol released/100 mg cell lipids/90 min. This 
sub­maximal stimulation of lipolysis represented an 
optimal condition to detect any putative induction or 
blockade by the tested agents. Figure 3 shows that the 
antilipolytic effect of a relatively high dose of insulin 
(100 nmol/L) was significant although incomplete. A 
similar partial antilipolytic effect was observed with 1 
mmol/L benzylamine only in the presence of 0.1 mmol/
L vanadate. The dose­dependent antilipolytic effect of 
B6V10 led to a stronger lipolysis inhibition than with 
insulin or benzylamine, at least when the conjugate was 
tested at 100 µmol/L (Figure 3A).
In freshly prepared human adipocyte suspensions, 
basal lipolysis was maximally activated by 10 µmol/L 
of isoprenaline (532% ± 107% of basal) but was 
unaltered by insulin alone (89% ± 16% of basal, n = 
10, not shown). The stimulation of glycerol release by 
the dose of isoprenaline used in mice (10 nmol/L) was 
also submaximal. This dose triggered the production of 
0.67 ± 0.08 µmol of glycerol/100 mg of cell lipids/90 
min in human adipocyte preparations, while basal 
release was 0.20 ± 0.07 µmol glycerol/100 mg lipids/90 
min. This lipolytic activation was considered as a 100% 
reference for testing the influence of insulin (100 nmol/
L), benzylamine (1 mmol/L), or increasing doses of 
B6V10 (1­100 µmol/L) (Figure 3B). All these agents 
partially but significantly limited the β­adrenergic­
induced lipolysis. When tested at 1 mmol/L, antilipolytic 
activity of benzylamine was as efficient as 100 µmol/L 
B6V10. The addition of vanadium did not enhance its 
effect (not shown). 
B6V10 reduces submaximal but not basal and 
maximally-stimulated lipolysis in human adipocytes
Further analyses of the B6V10 antilipolytic effect were 
performed on human adipocytes and showed that 1 
µmol/L of the conjugate could not impair the maximal 
lipolysis stimulation by 0.1, 1 or 10 µmol/L isoprenaline, 
while it impaired the submaximal β­adrenergic activa­
tion of glycerol release (Figure 4A). Similarly, no 
significant inhibition by B6V10 was detected on 1 nmol/L 
isoprenaline, when glycerol release values were close 
to basal levels. Moreover, B6V10 tended to limit the 
maximal effect of another strong lipolytic stimulator: 
The ANP, only active in human adipocytes[25,26] (Figure 
4B).
In agreement with our data obtained in rodent adipo­
cytes, micromolar doses of B6V10 were only limiting 
moderate lipolysis activation in human adipocytes. Thus, 
B6V10 appears to essentially hamper modest lipolytic 
activations, as those corresponding to the physiological 
modulation of triglyceride breakdown during interprandial 
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Figure 3  Comparison of the antilipolytic effects of B6V10 
and insulin in mouse and human adipocytes. Lipolysis was 
activated by 10 nmol/L isoprenaline and considered as a control 
set at 100% (iso alone, dotted line) while basal was set at 0% in: 
Mouse adipocytes (A) or human adipocytes (B). The observed 
lipolytic response to the β-adrenergic agonist was significantly 
reduced in the presence of insulin (100 nmol/L, closed triangle), 
benzylamine (1 mmol/L alone for humans, or combined with 
0.1 mmol/L vanadate for mouse adipocytes, closed circle), or 
increasing doses of B6V10 (1-100 µmol/L, red diamonds), at: aP < 
0.05, cP < 0.02, fP < 0.01. Mean ± SEM of 8 murine preparations (A) 
or 6-7 individual cases (B). 
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Stimulation of glucose transport into human adipocytes 
by B6V10
Lastly, we explored whether the conjugate B6V10 
could activate glucose transport in human adipocytes 
alongside its repression of triglyceride breakdown. 
In fact, previous studies that have demonstrated an 
insulin­like action of B6V10 on hexose uptake were 
restricted to murine adipocytes[13].
Here we show that freshly isolated human adipocyte 
preparations were highly sensitive to insulin, since 100 
nmol/L of the hormone induced a four­fold increase 
in basal 2­deoxyglucose uptake (Figure 5). There was 
no significant effect of B6V10 on glucose uptake when 
added at inframicromolar doses. However, at 10 and 
100 µmol/L, B6V10 reproduced approximately one third 
of the insulin stimulation of glucose transport, resulting 
in a highly significant activation. Sodium orthovanadate 
did not stimulate glucose uptake at 100 µmol/L and had 
no synergic effect with 10 or 100 µmol/L benzylamine. 
Indeed, when present at 0.1 mmol/L, benzylamine was 
as effective as 10 µmol/L B6V10 at stimulating hexose 
transport (Figure 5).
DISCUSSION 
The property of B6V10, a conjugate of benzylamine and 
decavanadate, to lower blood glucose has been reported 
together with in vitro demonstration of its ability to 
activate glucose transport and insulin signalling in 
adipocytes[13,14], while its ability to lower circulating FFAs 
in diabetic rats remains unexplained. Here we report for 
the first time that B6V10 is directly antilipolytic in murine 
and human adipocytes, a major finding regarding the 
growing interest for antilipolytic agents that may limit 
the harmful outcomes of lipotoxicity in diabesity[11,27,28]. 
Our observation using 1 µmol/L of the conjugate in 
human adipocytes, adds therefore a new insight to 
the development of vanadium­containing antidiabetic 
compounds, although it remains to avoid an overlap 
between their therapeutic and toxic doses. Accordingly, 
we are discussing below about the interest of inhibiting 
adipocyte lipolysis to reduce lipotoxicity, and about the 
possibility to develop vanadium­containing antidiabetic 
and anti­obesity agents that could become “drugable”, 
two issues independently covered in very recent 
reviews[5,29]. 
In diabesity, when AT has developed an insulin 
resistance, the fatty acid storage in hypertrophied 
adipocytes under the form of triglycerides becomes 
limited due to a decrease in lipogenic and antilipolytic 
action of insulin. Such reduced insulin responsiveness 
derepresses lipolysis in adipocytes and leads to ectopic 
FFA deposition (in liver, vessels, muscles, endocrine 
glands), which in turn hampers glucose utilization 
and lipid oxidation in all these organs. To combat this 
lipotoxicity, there is a need to control excessive FFA 
mobilization from AT that requires the characterization 
of potent antilipolytic factors and constitutes a novel 
therapeutic approach for the treatment of obesity 
complications. In fact, there is mounting evidence that 
antilipolytic agents limiting the release of non-esterified 
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Figure 4  Antilipolytic action of B6V10 in human adipocytes depends 
on prior lipolytic activation. Lipolysis was activated by: Increasing doses 
of isoprenaline (A) or high dose of atrial natriuretic peptide (ANP) (B), and 
without or with the indicated doses of B6V10 (red symbols). Mean ± SEM of 
6 determinations. Significantly different from corresponding condition without 
B6V10 at: aP < 0.05. 
a
Figure 5  Activation of glucose transport in human adipocytes by supra-
micromolar doses of B6V10. Suspensions of human fat cells (17 mg/400 
µL) were incubated 45 min without (basal, open circle) or the indicated 
concentrations of insulin (closed circles), B6V10 (red diamonds), benzylamine 
(open squares), and 100 µmol/L vanadate alone (yellow triangle) or in 
combination with benzylamine (closed triangles), then [3H]-2-deoxyglucose 
uptake was assayed on 10-min period. Mean ± SEM of 10 adipocyte 
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considered as antidiabetic or anti­obesity agents[5]. In 
this regard, the reversal of lipotoxicity is proposed to 
contribute to the beneficial effects of old drugs, such 
as pioglitazone. These “novel” properties are added 
to the anti­inflammatory properties of pioglitazone 
that improve metabolic and secretory functions in 
adipocytes and β­cells[27], and lead to re­examine this old 
antihyperglycemic agent as a treatment for non­alcoholic 
fatty liver disease (NAFLD) that often complicates type 
2 diabetes[28]. It is important to note that lipotoxicity can 
lead to severe NAFLD even when insulin resistance in AT 
is not concomitant with obesity. Indeed, the transgenic 
mice carrying fat-specific knockout of the insulin receptor 
are characterized by severe atrophy of fat depots, 
pronounced diabetes, and marked fatty liver disease[30]. 
Thus, it seems safer to limit ectopic lipid deposition by 
restricting excessive FFA release and blunting insulin 
resistance in adipocytes, even at the expense of 
maintaining adipose mass, than to overstimulate fat 
store mobilization. One has to keep in mind that one 
of the most powerful lipolytic agents, TNF­α, does not 
help in mitigating the deleterious outcomes of insulin 
resistance: On the opposite, it strongly desensitizes to 
insulin action and promotes inflammation.
Since we previously reported that chronic treatment 
with B6V10 lowered plasma FFA in diabetic rats[13], 
we asked whether this agent could be effective in 
lowering adipocyte lipolysis. In this comparative work, 
we brought compelling evidence that the conjugate 
inhibits lipolysis in rodent adipocytes with an efficiency 
greater than the ones obtained with its components 
used separately (benzylamine and decavanadate). 
Indeed, we have previously characterized B6V10 as an 
agent that exerts in adipocytes potent insulin­mimetic 
effects downstream the insulin receptor, in a manner 
that is sensitive to SSAO/VAP­1 inhibition and which 
reproduces the synergism between benzylamine and 
vanadate[13,14]. The effective doses of B6V10 in inhibiting 
lipolysis in rodent adipocytes are superimposable to 
those necessary for glucose transport stimulation. 
Moreover, our de novo lipogenesis experiments add to 
the list of B6V10 insulin­like effects[14] its capacity to 
activate glucose incorporation into the neosynthesized 
lipids in mouse adipocytes.
The fact that B6V10 was unable to impair maximal 
activation of lipolysis in all the models studied is not 
a concern since the amplitude of increased lipolytic 
activity of adipocytes is much lower in pathological 
states of insulin resistance than the activation that 
physiologically emerges during prolonged fasting or cold 
exposure[31]. Noteworthy, human adipocytes exhibited 
both lipolysis inhibition and glucose uptake activation 
in response to B6V10. Our data clearly show that the 
in vitro antilipolytic effect of a relatively high dose of 
insulin was not complete in subcutaneous adipocytes of 
sedentary women. Since insulin inhibited only by one­
third of the response to isoprenaline, and since this 
effect was fully reproduced by 1 µmol/L of B6V10 (i.e., 
at a dose only tenfold higher than that necessary for 
insulin), the conjugate can be definitely considered as a 
good insulin mimicker. Increasing the dose of B6V10 up 
to 100 µmol/L resulted in a higher but partial inhibition 
of lipolysis. Therefore, B6V10 could surpass insulin­
like antilipolytic action in adipocytes from overweight 
subjects, who exhibited weak insulin sensitivity, although 
being non­obese and non­diabetic. Yet, the insulin 
antilipolytic response appeared to be more altered in 
these individuals than the insulin activation of glucose 
transport. The latter reached a four­fold stimulation of 
basal uptake in our conditions, which does not denote 
a fully developed insulin­resistant state for human fat 
cells[32]. Describing the exact onset of these defects 
was not in the scope of our studies, but deserves to be 
performed in future clinical studies, taking into account 
the influence of gender and fat depot anatomical 
location. Actually, it can be noticed that the maximal 
antilipolytic response to B6V10 was lower in human 
adipocytes than in rat and mouse models. 
B6V10 is one of the promising antihyperglycaemic 
agents belonging to the wide family of vanadium deri­
vatives. It can be summarized that, once ingested, 
vanadium is found in the organism under a cationic 
(vanadyl) or anionic (vanadate) form, the latter resembl­
ing to a phosphate group. In fact, orthovanadate 
(H2VO4­) interacts with a pleiad of cellular components 
interacting with H2PO4­, e.g., enzymes influenced by 
(de)phosphorylation state. Yet, the ability of vanadium 
to mimic insulin actions in rat adipocytes has been 
reported in the 80s and univocally confirmed in all the 
insulin­sensitive tissues expressing GLUT4. Furthermore, 
we observed that vanadate and vanadyl were equally 
efficient in totally inhibiting rat adipocyte lipolysis at 1 
mmol/L[33]. The current issue of vanadium pharmacology 
is to take advantage of these insulin­like properties 
without the concerns raised by the high degree of 
vanadium toxicity (due to accumulation in tissues like the 
kidneys and bones); in other terms: Lowering the risk/
benefit ratio[29]. Among the various improvements raised 
by studies of chemico­biological interactions of vanadium 
derivatives[34], the vanadium peroxides, or pervanadates, 
formed by mixing vanadium and H2O2[16], have shown 
an increase in the potency for insulinomimetic actions 
in adipocytes[29]. With pervanadates, the effective 
doses were lowered from millimolar to micromolar 
range, as they are irreversible inhibitors of various 
phosphatases and act on target cells at much lower 
doses than vanadate. Recently, we synthesized and 
characterized salts composed by arylalkylamines 
combined with decavanadate that permitted to lower 
the effective antidiabetic dose of vanadium to non­
toxic levels. The more active compound of this series, 
namely B6V10, mixes decavanadate, a complex form 
that increases adipocyte glucose uptake more potently 
than other vanadium forms[35], with benzylamine, 
also behaving as an insulin mimicker in human fat 
cells[36]. These two halves were already described to act 
synergistically, especially in fat cells where benzylamine 
is oxidized by the highly expressed SSAO/VAP­1, 
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thereby generating hydrogen peroxide[37], which in turn 
reacts with vanadate to generate peroxovanadate. This 
compound then inhibits protein tyrosine phosphatases 
and triggers glucose carrier translocation and hexose 
transport activation[38]. This cascade of events results 
in a substantial antihyperglycaemic action in diabetic 
rodents that is more potent than the separate effects 
of benzylamine and vanadate[39]. All these insulin­like 
actions disappear when SSAO/VAP­1 is pharmacologically 
inhibited or genetically invalidated[40]. Thus, when B6V10 
undergoes oxidation by SSAO/VAP­1, it generates 
peroxovanadate and acts in vitro[16] as well as in vivo[14] 
to trigger antidiabetic actions. By releasing the real active 
vanadium­based ligands that interact with phosphatases 
near the target cells, the B6V10 is therefore a mean to 
improve decavanate “speciation” (see review from Scior 
and coworkers for further details[29]) and to circumvent 
the concerns raised by decavanadate toxicology[41].
Our in vitro analysis reveals a potent antilipolytic 
action of B6V10, which might be helpful in combating the 
lipotoxicity that participates to diabesity complications. 
Several concerns to this therapeutic potential could 
be raised since our experiments were performed only 
in adipocytes isolated from subcutaneous abdominal 
depots of overweight women. 
The first concern could be the relevance of our obser-
vations for visceral adipocytes from massively obese 
subjects, considered as more harmful. Indeed, clinical 
studies have demonstrated that impaired triglyceride 
storage also occurs in the subcutaneous AT of insulin­
resistant individuals when compared to their BMI­
matched controls classified as insulin­sensitive[42]. 
Using deuterated water prolonged administration 
and functional exploration of subcutaneous AT, these 
studies elegantly indicated that, during the onset of 
type 2 diabetes in humans, there was a clear defect in 
insulin suppression of lipolysis and activation of de novo 
lipogenesis in the subcutaneous adipocytes themselves. 
A second concern could be raised regarding the fact 
that we have only determined glycerol release as an 
index of lipolysis, while lipotoxicity is mainly supported 
by excessive FFA release. Previous studies on AT 
lipolysis and insulin sensitivity have evidenced a tight 
relationship between spontaneous glycerol production 
by human AT explants and insulin resistance in a large 
cohort of subjects presenting a wide range of BMI[43]. 
According to Girousse et al[43], both lipolysis end­
products, glycerol and FFAs, were equivalent to show 
that partial inhibition of AT lipolysis improves insulin 
sensitivity[43]. 
Another limitation regarding the maximal antilipolytic 
capacity of B6V10 is that it is not complete and can be 
surpassed by various stronger antilipolytic agents (such 
as nicotinic acid, purinergic or α2­adrenergic agonists, 
see[32]). However, these agents are unable to activate 
glucose uptake in human adipocytes (C. Carpéné 
unpublished observations) and do not offer the dual 
interest of B6V10 to lower both circulating glucose and 
lipids. 
Lastly, insulin also plays lipogenic and antilipolytic 
actions when infused into the hypothalamus of rats[44]. 
Whether B6V10 also mimics insulin actions in the brain, 
in a manner that could influence its antidiabetic and 
lipid­lowering action during chronic treatment remains 
unknown and deserves further in vivo studies in insulin­
resistant models.
Though being clearly antilipolytic in human adipo­
cytes, 1 µmol/L B6V10 was not more effective than 1 
mmol/L benzylamine, and the combination of vanadate 
with benzylamine did not lead to the synergism found 
in rat adipocytes. Indeed, in human AT, the maximal 
antilipolytic effect of B6V10 was comparable to that 
of benzylamine, already described to hamper about 
one­half of stimulated lipolysis[36]. Regarding the 
glucose uptake in human adipocytes, B6V10 is clearly 
stimulating, but there is no synergism between its 
components, benzylamine and vanadate, each one 
reproducing at 100 µmol/L the effect of 10 µmol/L 
conjugate. This is in apparent agreement with the 
proposed lack of glucose transport activation by deca­
vanadate in human adipocytes[35], and confirms the 
absence of potentiation between SSAO/VAP­1 substrates 
and vanadium regarding glucose transport in human 
adipocytes[33]. Therefore, while noticeable synergism 
between SSAO/VAP­1 substrates and decavanadate 
occurs when using B6V10 in murine adipocytes, this 
apparently does not work as well in human fat cells, for a 
reason that remains to be elucidated. 
Consequently, our comparative approach indicates 
that B6V10 cannot be immediately considered for 
clinical application as an efficient mean to increase the 
benefit/risk ratio of vanadium regarding its therapeutic 
antidiabetic indication. Nevertheless, it must be noted 
that, although B6V10 is not the most potent and 
powerful antilipolytic agents described so far in human 
adipocytes, it combines two insulin­like actions: Limiting 
lipolysis and increasing glucose uptake. In this regard, 
it should be considered as a valuable candidate to 
further develop an approach based on the mitigation 
of lipotoxicity in diabesity. This adds an alternative to 
classical antilipolytic agents proposed to limit lipotoxicity, 
such as nicotinic acid (Acipimox)[12], or lipase inhibitors[5]. 
Another consequence of our depicted interspecies 
differences is that the exploration of the antilipolytic 
properties in human adipose cells deserves to be applied 
to other vanadium conjugates recently tested with 
success on diabetic rodents, such as those combining 
metformin and decavanadate[45].
In conclusion, the conjugate of benzylamine and 
decavanadate B6V10 exerts insulin­like actions in human 
adipocytes, including lipolysis inhibition and glucose 
transport activation. 
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Insulin resistance of adipocytes in hypertrophied fat depots leads to an increased 
lipolytic activity releasing in the circulation excessive amounts of free fatty acids 
(FFA) that accumulates under the form of triglyceride-rich ectopic lipid droplets in 
liver and muscles. The conjugate salt hexaquis(benzylammonium) decavanadate 
has been reported to lower circulating glucose and FFA in diabetic rodents, but 
its direct action of adipocyte lipolytic activity has never been assessed.
Research frontiers
This in vitro approach definitely brings evidence that B6V10 reproduces the rapid 
antilipolytic action of insulin in murine and human fat cells. At 100 µmol/L, B6V10 
even surpasses the maximal inhibition of lipolysis induced by the pancreatic 
hormone. Since the molecule also stimulates glucose uptake in human 
adipocytes and has been demonstrated to exert antihyperglycemic actions in 
murine models of diabetes, it can be qualified as insulin mimicker. 
Innovations and breakthroughs
In vitro, B6V10 exerts various insulin-like actions in human adipocytes including 
lipolysis inhibition and glucose uptake activation. This conjugate salt of 
benzylamine and decavanadate has the potential to alleviate the deleterious 
complications linked to the insulin resistance of adipocyte antilipolytic/lipogenic 
activities emerging in morbid obese and diabetic patients, and could be 
considered as a potential antidiabetic agent. 
Applications 
B6V10 could be useful as an auxiliary therapy in limiting the lipotoxicity related to 
obesity and insulin resistance. Its chronic administration might delay ectopic fat 
deposition and should reduce hepatic steatosis whether active in obese patients 
at doses acting in fat stores without exerting adverse effects elsewhere in the 
organism.
Terminology 
ANP: Atrial natriuretic peptide; AT: Adipose tissue; BMI: Body mass index; 
B6V10: Hexaquis(benzylammonium) decavanadate; FFA: Free fatty acids; 
GLUT4: Insulin-sensitive glucose transporter; H2O2: Hydrogen peroxide; SEM: 
Standard error of the mean; SSAO/VAP-1: Semicarbazide-sensitive amine 
oxidase, identical to VAP-1 (vascular adhesion protein-1).
Peer-review
Manuscript presents solid data and is of good quality. 
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